

# Index

6-OHDA, 89

$\alpha$ -synuclein, 12, 13, 54

## A

Amantadine, 137

Animal models, 83

Anticholinergics, 136

Antigen presentation, 33

Apoptosis, 65

Apoptotic pathways, 67

Arthritis, 124

Autophagy, 16, 50, 51

Autosomal dominant, 8, 31

Autosomal recessive, 8, 31

## B

B lymphocyte, 37

Braak staging, 12

Bradykinesia, 110

Brain iron accumulation, 122

## C

Caffeine, 6

Caspases, 66

Catechol-O-methyl transferase inhibitors, 135

Cell types, 167

Cell-based therapies, 162

Cigarette smoking, 6

Clinical aspects, 45, 54

Clinical features, 3

Corticobasal syndrome, 117

## D

Deep brain stimulation device, 150

Deep brain stimulation, 145

Dementia, 115

Depression, 124

Diagnosis, 110

Diagnostic criteria, 111

Differential diagnosis, 109, 148

Disease progression, 114

DJ-1, 96

Dopamine agonists, 133

Dopamine, 131

Dopaminergic, 3

Drug-induced parkinsonism, 117

Dysfunctional protein, 15

Dystonic tremor, 123

## E

Embryonic stem cells, 165

Emerging treatments, 137

Environmental factors 38

ER-stress, 54

Essential tremor, 123

Etiology, 3, 6, 28

Extrinsic apoptotic pathway, 69

## F

Familial, 9, 92, 119

Fragile X-associated tremor, 121

Fronto-temporal dementia, 121

**G**

Gain of function, 49  
 Gaucher disease, 48  
 GBA1 gene, 46  
 GBA1 mutation, 45, 48  
 Genetic causes, 119  
 Genetic models, 91, 92, 93  
 Genetics, 7  
 Globus pallidus internus, 153  
 Glucocerebrosidase, 46  
 GPi, 153, 154

**H**

Heavy metals, 7  
 Herbicides, 7, 90  
 HLA haplotypes, 34  
 HLA, 33, 35, 36  
 Human leukocyte antigen, 33  
 Huntington's disease, 120

**I**

Idiopathic, 110, 122  
 IFN- $\gamma$ , 37  
 Immunogenetics, 27, 32  
 Induced pluripotent stem cells, 167  
 Inflammation, 37  
 Intrinsic apoptotic pathway, 68

**L**

Levodopa, 132  
 Lewy bodies, 115  
 Lewy body, 11  
 Loss of function, 49  
 LRRK2, 96  
 Lysosome, 50

**M**

Macroautophagy, 51  
 Metabolic pathway, 37, 131  
 Mitochondrial disorders, 122  
 Mitochondrial dysfunction, 14, 53  
 Monoamine oxidase B inhibitors, 135  
 Monogenic, 29  
 MPTP, 87  
 Multiple system atrophy, 115

**N**

Neurodegeneration, 122  
 Neurodegenerative causes, 114  
 Neuroimaging, 56  
 Neuroinflammation, 16  
 Neuropathology, 3, 8  
 Neurotoxic models, 87  
 NF- $\kappa$ B, 37  
 Nigrostriatal, 3  
 Non-human primates, 86  
 Non-mammalian species, 86  
 Non-motor features, 113  
 Non-neurological differential, 124  
 Normal-pressure hydrocephalus, 119

**O**

Obsessional slowness, 124  
 Outcome data, 152  
 Oxidative stress, 53

**P**

PARK-designated genes, 9  
 Parkinson's disease, 3, 27, 45, 65, 83, 109,  
 129, 145, 161  
 Pathogenic mechanisms, 48  
 Pathological mechanisms, 45

Patient selection, 146  
Pedunculo pontine nucleus, 155  
Pesticides, 7, 90  
Pharmacological treatment, 129  
PINK1, 96  
Preformed fibril models, 95  
PRKN, 96  
Progressive supranuclear palsy, 116  
Psychogenic parkinsonism, 125

## R

Rigidity, 113  
Rodents, 85

## S

Secondary causes, 117  
Single nucleotide polymorphisms, 33  
SNPs, 32, 33, 35, 36  
Spinocerebellar ataxia, 121  
Stem cell, 161  
STN, 153, 154  
Substantia nigra pars compacta, 10  
Subthalamic nucleus, 151  
Surgical procedure, 150

## T

T lymphocyte, 37  
Target selection, 145  
Therapeutic implications, 73  
Therapeutic prospects, 56  
Toxins, 118  
Transcription factors, 97  
Transgenic models, 91  
Treatment, 161  
Tremor, 112, 123

## U

Ubiquitin-proteasome, 15  
UCH-L1, 96

## V

Vascular parkinsonism, 118  
Ventralis intermediate nucleus, 155  
Viral vector-mediated models, 94

## W

Wilson's disease, 120

Doi: <http://dx.doi.org/10.15586/codonpublications.parkinsonsdisease.2018.ind>